Industry

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in November: Piper Sandler 34th Annual Healthcare Conference: Fireside Chat at 2:00 p.m. ET on … [Read more…]

2023 Revenue Covenant tied to percentage of Company’s annual operating plan and substantially waived if Company raises $15 million of new funding Liquidity Covenant reduced to $5 Million Option to pay a portion of loan interest “in kind” to provide additional flexibility EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical … [Read more…]

In KEYNOTE-859, KEYTRUDA® (pembrolizumab) combined with chemotherapy demonstrated statistically significant overall survival, progression-free survival, and overall response rate for patients regardless of PD-L1 expression RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 KEYNOTE-859 trial investigating KEYTRUDA, Merck’s … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–$JANX—Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at two upcoming investor conferences and be available for 1×1 … [Read more…]

MUNICH–(BUSINESS WIRE)–CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the continued, … [Read more…]

 ROUNDHEAT TOBACCO SYSTEMTM Unlocks Affordable, Bladeless-Heating Technology from the World’s No. 1 Heated Tobacco System1, IQOS LAUSANNE, Switzerland–(BUSINESS WIRE)–Philip Morris International Inc. (PMI) (NYSE: PM) today announced the launch of its latest heat-not-burn tobacco heating system, BONDS by IQOS with its accompanying specially designed tobacco sticks, BLENDS. A new product from IQOS, the world’s No. … [Read more…]

– RWTH Aachen University One of Europe’s First Universities to Offer EnChroma Colourblind Glasses for Students and Staff to Borrow – AACHEN, Germany & BERKELEY, Calif.–(BUSINESS WIRE)–#enchroma—VORSCHUB at RWTH Aachen University today announced that colourblind students and staff will now be able to borrow EnChroma colourblind glasses on campus to help them overcome the obstacles … [Read more…]

— Turbine’s Simulated Cell™ platform identifies novel cancer treatments and high unmet need patient groups to target where current experimental or computational approaches fail to succeed LONDON & BUDAPEST, Hungary–(BUSINESS WIRE)–Turbine, a company developing a cell behavior simulation platform, today announced the closing of a €20 million Series A financing round. Mercia and MSD Global … [Read more…]

Instrument-Free Veros™ COVID-19 Produces Highly Accurate Molecular Results in about 15 minutes BOSTON & OXFORD, England & CAMBRIDGE, England & AMSTERDAM–(BUSINESS WIRE)–Global molecular diagnostics innovator Sense Biodetection (Sense) today announced it has entered into a strategic agreement with R-Biopharm Nederland B.V. for the non-exclusive distribution in the Netherlands, Belgium, and Luxembourg of Sense’s Veros instrument-free, … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL). Dr. Jasmine Cui, Co-founder, Chairwoman and CEO … [Read more…]